The New Face of Traditional Chinese Medicine

See allHide authors and affiliations

Science  10 Jan 2003:
Vol. 299, Issue 5604, pp. 188-190
DOI: 10.1126/science.299.5604.188

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


TOKYO-- This year, the U.S. Food and Drug Administration approved a phase II trial to test the efficacy of Kanglaite in treating non-small-cell lung cancer, making Kanglaite the first drug derived from a traditional Chinese herbal remedy to go into clinical trials in the United States. Asian governments are hoping that high-volume screening and rigorous clinical trials will unlock the secrets of ancient herbal remedies--and that the results will pass muster with Western scientists.